HIPRA welcomes the European Commission's efforts to develop a proposal for an EU Biotech Act. We believe that Europe is at a crucial juncture and, as highlighted in the Draghi report, the pharmaceutical industry plays a vital strategic role in the European economy.
HIP
HIPRA
Company · Spain
2
positions filed
in the 665 files tracked
2
legislative files
of 665 tracked
2
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Track HIPRA in PolicySpeak: request access →
Work at HIPRA? so we know who speaks for it.
Their record over time
HIPRA filed 2 positions between 10 Jun 2025 and 1 Oct 2025, across 2 of the 665 legislative files tracked here, attaching a full position paper 2 times.
What they argued
HIPRA strongly supports the European Commission's ongoing efforts in shaping the European Innovation Act (EIA) and welcomes the opportunity to contribute to this important consultation. As a dynamic biotech company, HIPRA is at the forefront of innovations in both human and animal health, actively contributing to the EU's goals of strengthening public health preparedness and advancing its strategic autonomy.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put HIPRA next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 31.
Is this your organization?
Everything on this page comes from HIPRA’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.